Molecular and Cellular Biochemistry

, Volume 433, Issue 1–2, pp 205–211 | Cite as

Different effects of neuropeptide Y on proliferation of vascular smooth muscle cells via regulation of Geminin

Article
First Online:
Received:
Accepted:

Abstract

The proliferation-promoting effect of neuropeptide Y (NPY) always functions in low-serum-cultured vascular smooth muscle cells (VSMCs), and the phenotypic switch of VSMCs is regulated by concentrations of serum. Whether the property of the NPY proliferative effect in VSMCs relies on phenotype of VSMCs is unclear. We aimed to explore the role of NPY on proliferation of different VSMC phenotypes in the pathogenesis of atherosclerosis. By stimulating A10 cells with 200 nM NPY in 0.5 or 10% serum, 3H-thymidine and 5-ethynyl-2′-deoxyuridine (EdU) and CCK8 measurements were used to detect VSMC proliferation. RT-PCR and Flow cytometry were performed to detect the factors involved in different properties of the NPY proliferative effect in VSMCs. Instead of facilitating proliferation, NPY had no significant effect on the growth of VSMCs when cultured in 10% serum (VSMCs stayed at synthetic states). The underlying mechanism may be involved in down-regulation of Y1 receptor (P < 0.05 vs. Vehicle) and up-regulation of Geminin (P < 0.05 vs. Vehicle) in 10% serum-cultured VSMCs co-incubated with 200 nM NPY. Besides, modulation of Geminin was effectively blocked by the Y1 receptor antagonist. The stimulation of NPY on proliferation of VSMCs could be a double-edged sword in the development of atherosclerosis and thus provides new knowledge for therapy of atherosclerosis.

Keywords

NPY Geminin Vascular smooth muscle cells (VSMCs) Serum Phenotype 
This is a preview of subscription content, log in to check access.

Notes

Funding

This study was supported by the National Natural Science Foundation of China (No. 81570396).

Compliance with ethical standards

Conflict of interest

We declare there was no commercial, proprietary, or financial interest conflict in the products or companies described in this article.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249–1256. doi: 10.1038/nm1102-1249 CrossRefPubMedGoogle Scholar
  2. 2.
    Legein B, Temmerman L, Biessen EA, Lutgens E (2013) Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 70:3847–3869. doi: 10.1007/s00018-013-1289-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Schachter M (1997) Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. Int J Cardiol 62(Suppl 2):S85–S90CrossRefPubMedGoogle Scholar
  4. 4.
    Hao H, Gabbiani G, Bochaton-Piallat ML (2003) Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23:1510–1520. doi: 10.1161/01.ATV.0000090130.85752.ED CrossRefPubMedGoogle Scholar
  5. 5.
    Rensen SS, Doevendans PA, van Eys GJ (2007) Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 15:100–108CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lobaugh LA, Blackshear PJ (1990) Neuropeptide Y stimulation of myosin light chain phosphorylation in cultured aortic smooth muscle cells. J Biol Chem 265:18393–18399PubMedGoogle Scholar
  7. 7.
    Herring N (2015) Autonomic control of the heart: going beyond the classical neurotransmitters. Exp Physiol 100:354–358. doi: 10.1113/expphysiol.2014.080184 CrossRefPubMedGoogle Scholar
  8. 8.
    Pons J, Kitlinska J, Jacques D, Perreault C, Nader M, Everhart L, Zhang Y, Zukowska Z (2008) Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Can J Physiol Pharmacol 86:438–448. doi: 10.1139/y08-054 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhu P, Sun W, Zhang C, Song Z, Lin S (2016) The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. Int J Cardiol 220:235–241. doi: 10.1016/j.ijcard.2016.06.138 CrossRefPubMedGoogle Scholar
  10. 10.
    Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H (1998) Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75–76:231–238CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang P, Qi YX, Yao QP, Chen XH, Wang GL, Shen BR, Han Y, Gao LZ, Jiang ZL (2015) Neuropeptide Y stimulates proliferation and migration of vascular smooth muscle cells from pregnancy hypertensive rats via Y1 and Y5 receptors. PLoS ONE 10:e0131124. doi: 10.1371/journal.pone.0131124 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Crnkovic S, Egemnazarov B, Jain P, Seay U, Gattinger N, Marsh LM, Balint Z, Kovacs G, Ghanim B, Klepetko W, Schermuly RT, Weissmann N, Olschewski A, Kwapiszewska G (2014) NPY/Y(1) receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension. Br J Pharmacol 171:3895–3907. doi: 10.1111/bph.12751 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Reusch P, Wagdy H, Reusch R, Wilson E, Ives HE (1996) Mechanical strain increases smooth muscle and decreases nonmuscle myosin expression in rat vascular smooth muscle cells. Circ Res 79:1046–1053CrossRefPubMedGoogle Scholar
  14. 14.
    Wilson E, Mai Q, Sudhir K, Weiss RH, Ives HE (1993) Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF. J Cell Biol 123:741–747CrossRefPubMedGoogle Scholar
  15. 15.
    Chistiakov DA, Orekhov AN, Bobryshev YV (2015) Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf) 214:33–50. doi: 10.1111/apha.12466 CrossRefGoogle Scholar
  16. 16.
    Bina RB, Hill N, Brem AS (1998) Effect of serum on vascular smooth muscle function. Life Sci 62:1195–1201CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang Y, Jiang Z, Li L, Zhou Y, Song Z, Shu M (2014) Geminin interference facilitates vascular smooth muscle cell proliferation by upregulation of CDK-1. Cardiovasc Drugs Ther 28:407–414. doi: 10.1007/s10557-014-6550-9 CrossRefPubMedGoogle Scholar
  18. 18.
    Zhou Y, Shi W, Luo H, Yue R, Wang Z, Wang W, Liu L, Wang WE, Wang H, Zeng C (2015) Inhibitory effect of D1-like dopamine receptors on neuropeptide Y-induced proliferation in vascular smooth muscle cells. Hypertens Res 38:807–812. doi: 10.1038/hr.2015.84 CrossRefPubMedGoogle Scholar
  19. 19.
    Yulyaningsih E, Zhang L, Herzog H, Sainsbury A (2011) NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 163:1170–1202. doi: 10.1111/j.1476-5381.2011.01363.x CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Suchyta M, Miotto B, McGarry TJ (2015) An inactive geminin mutant that binds cdt1. Genes (Basel) 6:252–266. doi: 10.3390/genes6020252 CrossRefGoogle Scholar
  21. 21.
    Karamitros D, Kotantaki P, Lygerou Z, Veiga-Fernandes H, Pachnis V, Kioussis D, Taraviras S (2010) Life without geminin. Cell Cycle 9:3181–3185. doi: 10.4161/cc.9.16.12554 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lagraauw HM, Westra MM, Bot M, Wezel A, van Santbrink PJ, Pasterkamp G, Biessen EA, Kuiper J, Bot I (2014) Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. Atherosclerosis 235:196–203. doi: 10.1016/j.atherosclerosis.2014.04.025 CrossRefPubMedGoogle Scholar
  23. 23.
    Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY, Kim K (2008) Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 51:71–77. doi: 10.1097/FJC.0b013e31815bd23d CrossRefPubMedGoogle Scholar
  24. 24.
    Saleh Al-Shehabi T, Iratni R, Eid AH (2016) Anti-atherosclerotic plants which modulate the phenotype of vascular smooth muscle cells. Phytomedicine 23:1068–1081. doi: 10.1016/j.phymed.2015.10.016 CrossRefPubMedGoogle Scholar
  25. 25.
    Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z (2003) Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol 81:177–185. doi: 10.1139/y02-166 CrossRefPubMedGoogle Scholar
  26. 26.
    Shalaw FG, Slimani S, Kolopp-Sarda MN, Marchand M, Faure G, Stoltz JF, Muller S (2006) Effect of cyclic stretching and foetal bovine serum (FBS) on proliferation and extra cellular matrix synthesis of fibroblast. Biomed Mater Eng 16:S137–S144PubMedGoogle Scholar
  27. 27.
    Murphy LO, Cluck MW, Lovas S, Otvos F, Murphy RF, Schally AV, Permert J, Larsson J, Knezetic JA, Adrian TE (2001) Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer 84:926–935. doi: 10.1054/bjoc.2001.1698 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Cardiology, Southwest HospitalThird Military Medical UniversityChongqingChina
  2. 2.School of Health Science, IIIawarra Health and Medical Research InstituteUniversity of WollongongWollongongAustralia

Personalised recommendations